Indivior Pharmaceuticals (INDV) Cash from Financing Activities (2024 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Cash from Financing Activities of $7.0 million for Q1 2026, up 141.18% year-over-year from $2.9 million in Q1 2025, and up 240.0% quarter-over-quarter from -$5.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Cash from Financing Activities (2024 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $7.0 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 141.18% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at -$6.0 million (up 90.48% YoY), while the FY2025 annual figure was -$30.0 million, up 70.59% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $7.0 million, up from -$5.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $40.0 million in Q4 2024, with the low at -$56.0 million in Q1 2024.
- The 3-year median for Cash from Financing Activities is -$5.0 million (2025), against an average of -$13.9 million.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities tumbled 112.5% in 2025, then soared 141.18% in 2026.
- Indivior Pharmaceuticals' Cash from Financing Activities stood at $40.0 million in 2024, then sank by 112.5% to -$5.0 million in 2025, then jumped by 240.0% to $7.0 million in 2026.
- Business Quant data shows INDV's Cash from Financing Activities at $7.0 million in Q1 2026, -$5.0 million in Q4 2025, and -$3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Indivior Pharmaceuticals | 4.51 Bn | 4.29 Bn | 294.00 Mn | -173.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -173.00 Mn |
| Jun 30, 2026 | -173.00 Mn |
| Mar 31, 2026 | 7.00 Mn |
| Mar 31, 2026 | 7.00 Mn |
| Dec 31, 2025 | -5.00 Mn |
| Dec 31, 2025 | -5.00 Mn |
| Sep 30, 2025 | -3.00 Mn |
| Sep 30, 2025 | -3.00 Mn |
| Jun 30, 2025 | -5.00 Mn |
| Jun 30, 2025 | -5.00 Mn |
| Mar 31, 2025 | -17.00 Mn |
| Mar 31, 2025 | -17.00 Mn |
| Dec 31, 2024 | 40.00 Mn |
| Dec 31, 2024 | 40.00 Mn |
| Sep 30, 2024 | -51.00 Mn |
| Sep 30, 2024 | -51.00 Mn |
| Jun 30, 2024 | -35.00 Mn |
| Jun 30, 2024 | -35.00 Mn |
| Mar 31, 2024 | -56.00 Mn |
| Mar 31, 2024 | -56.00 Mn |